An ongoing randomized double-blinded trial comparing the effectiveness of two weeks of Elagolix, an oral GnRH receptor antagonist versus placebo prior to IVF in patients with endometriosis, will shed light on the use of this class of drugs that have recently been shown to be effective for the improvement of endometriosis-related symptoms [52,53]. Here, GNRHR is linked to endometriosis.